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Background: Few studies on Cytomegalovirus (CMV) infection in adult-to-adult living donor 
liver transplantation (LDLT) have been reported.  The aim of this study was to analyze the 
incidence, risk factors, and management of CMV infection after LDLT.   
Methodology: Retrospective analysis was performed with 72 consecutive adult cases.   
Results: CMV antigenemia was demonstrated in 31 (43.1%) patients and 9 patients (12.5%) 
manifested fever.  Twelve patients were treated with intravenous ganciclovir (GCV) injection.  
There was improvement in 10 patients, while in one patient who had an adverse effect, foscanet 
was administered concomitant with CMV-IG, resulting in improvement, and the death of the 
another one from sepsis.  Twelve patients were given oral valganciclovir (VGCV), and all 
showed improvement.  ABO incompatible transplantation was associated with CMV infection 
after LDLT in both the univariate (p=0.005) and multivariate analyses (p=0.04).  After 
discharge, 12 out of 63 patients (19%) suffered from CMV infection and all of them were taking 
steroid.   
Conclusion: ABO incompatible transplantation was demonstrated as a risk factor for CMV 
infection during hospitalization.  After discharge, immunosuppressive status seemed to be 
more essential as a predictor for CMV infection.  Routine examination to detect CMV 
antigenemia is needed, especially in patients with potentially over-immunosuppressive 







 Cytomegalovirus (CMV) is an ubiquitous herpes virus that infects 60 – 100% of 
humans, primarily in the first two decades of life (1-3).  In most cases, after primary infection, 
CMV remains and individuals with normal immunity will not have any symptoms for the rest 
of their lives (3, 4).  Around 40 to 50% of recipients undergoing liver transplantation suffer 
from CMV infection (4-6).  Infection with CMV may occur asymptomatically (CMV infection) 
or as a symptomatic illness (CMV disease) (4, 7-9).  In addition to its directly attributable 
effects, CMV is known as an immunomodulator virus that upregulates alloantigen, thereby 
increasing the risk of acute and chronic rejection and predisposing recipients to other 
opportunistic infections and Epstein-Barr virus-associated post transplant lymphoproliferative 
disorders (3, 8 ).   
 Although a marked decrease in the incidence and severity of CMV infection, and 
associated mortality after liver transplantation, has been achieved, CMV infection is one of the 
most common infectious complications after liver transplantation even now and is known to 
have adverse effects on transplant outcome (3, 4, 8).  We herein review the present state of 




From August 1997 to February 2008, 82 consecutive LDLTs were performed with 79 patients in 
our hospital.  Nine patients who were younger than 15 years old and one patient whose 
medical record could not be located were excluded from this study.  We assessed the remaining 
72 cases until one year after LDLT.  Out of 72 patients, 47 (65.3%) were male, and the age 
range was 16 to 68 years (mean: 51.5 years).  The underlying liver diseases were as follows: 
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hepatitis C virus-related liver cirrhosis (LC) with or without hepatocellular carcinoma (HCC) 
(26 patients, 36.1%), hepatitis B virus-related LC with or without HCC (16 patients, 22.2%), 
fulminant hepatic failure (7 patients, 11.7%), primary biliary cirrhosis (6 patients, 8.3%), 
alcohol-induced LC (4 patients, 5.6%), graft failure (3 patients, 5.0%), congenital biliary atresia 
(2 patients, 3.3%), cryptogenic LC with or without HCC (2 patients, 3.3%), and non-alcoholic 
steatohepatitis, Budd-Chiari syndrome, primary sclerosing cholangitis, idiopathic portal 
hypertension, Caroli disease, and autoimmune hepatitis (1 patient each).   
Immunosuppression after LDLT 
 Basically, the patients were administered a calcineurin inhibitor (tacrolimus or 
cyclosporine A) and corticosteroids as primary immunosuppressive therapy. 
Methylprednisolone was injected intravenously during surgery at a dose of 20 mg/kg and at a 
dose of 2 to one mg/kg/day tapered for 1 to 6 postoperative days followed by oral predonine at 
0.3 mg/kg/day (7 to 28 days), 0.2 mg/kg/day (after 28days), and discontinued in 3 months to one 
year.  If acute cellular rejection was proven, bolus injections of methylprednisolone were 
started.  In addition to the above-mentioned therapy, the ABO-incompatible LDLT recipients 
underwent more intensive immunosuppressive therapy, in that they were given rituximab, a 
monoclonal chimeric human-murine anti-CD20 antibody, to deplete the B cells one week before 
surgery, and took apheresis and/or double-filtration plasmapheresis to reduce the anti-A or 
anti-B antibody titers perioperatively.  To control the local intravascular coagulation in the 
graft, prostaglandin E1 for 3 weeks and methylprednisolone for 2 weeks were infused through a 
catheter that was put into the hepatic artery or portal vein.  In addition, mycophenolate 
mofetil (MMF) was given as soon as possible after transplantation. 
Surveillance in infection of CMV 
Before LDLT, serum IgG against CMV was measured in both donors and recipients.  After 
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LDLT, pp65 CMV antigens in peripheral blood leukocytes were determined once a week 
routinely until the recipients were discharged.  After discharge, if the patients showed any 
clinical symptoms or findings, we carried out tests to detect whether the virus was present.  
For the purpose of prophylaxis against virus infection, acyclovir or valacyclovir (after 2005) was 
given orally 3 months after LDLT.   
Treatments 
 When CMV antigenemia was proven, ganciclovir (GCV) was given intravenously or 
valganciclovir (VGCV) orally as preemptive therapy or targeted therapy.  
Risk factor analysis 
 The 18 variables were assessed in relation to CMV infection after LDLT (Table 1).   
Statistical analyses 
 Univariate analysis was used to ascertain the relationships between each variable 
and CMV infection.  The chi-square test or, for small numbers, Fisher’s exact test was used for 
comparison of categorical data.  Continuous variables were compared using the t test.  A p 
value of <0.05 was considered statistically significant.  For multivariate analysis, the factors 
identified as being associated with a p value ≦0.10 were entered into a stepwise logistic 
regression analysis to determine the independent risk factors for infections.   
 
Results 
CMV infection during hospitalization 
 After LDLT, 31 patients (43.1%) showed CMV antigenemia during their hospital stay.  
Of all the 31 patients, CMV disease occurred in 9 patients (12.5%), manifesting with fever.  
Among 22 asymptomatic patients, 4 were treated with GCV injection and 11 with VGCV and 
all of them were improved (Figure 1).  One patient with no treatment died of multiple organ 
failure unrelated to CMV infection.  Eight symptomatic patients were treated with GCV 
 6 
injection and there was improvement in 6 patients.  In the one patient, it was necessary to 
substitute foscanet and administer it concomitant with CMV-IG in place of GCV because of an 
adverse effect, namely, pancytopenia.  Another patient died of Methicillin-Resistant 
Staphylococcus Aureus sepsis and multiple organ failure.  One symptomatic patient was given 
VGCV with showing improvement.   
 The characteristics of the CMV-infected and non-infected patients are compared in 
Table 1.  In the variables, ABO incompatible transplantation was found to be associated with 
CMV infection after LDLT in the univariate analysis (p=0.005).  In the multivariate analysis, 
only ABO incompatible transplantation was found to be an independent predictor for CMV 
infection (odds ratio: 5.89, p=0.04) (Table 2).   
CMV infection in outpatients 
 During the study period, 9 out of 72 patients died during their hospitalizations, and 
we therefore assessed the remaining 63 patients.  CMV antigenemia was demonstrated in 12 
patients (19.0%) after discharge (Table 3).  Nine patients who did not show any symptoms and 
one suffering from fever survived with the treatment of GCV or VGCV.  The remaining 2 
patients showed CMV disease.  A sixty-five year old female patient (#5), who had undergone 
LDLT for idiopathic portal hypertension 4 months before, complained of abdominal pain and 
diarrhea due to CMV infection.  Although she was initially treated with intravenous GCV 
administration, she discontinued the use of the reagent because of pancytopenia due to 
hemophagocytosis.  Foscanet was then given, resulting in death from perforation of the 
intestinal wall.  Another patient, a 65 year-old woman who had received a transplant for 
hepatitis C virus-related LC with HCC 7 months before (#12), was admitted because of biliary 
stricture and cholangitis.  She suffered from high fever and abdominal pain due to CMV 
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infection 11 months after the LDLT operation.  Although GCV administration resulted in 
improvement of CMV antigenemia, she died of graft failure accompanied with biliary 
complication and Hepatitis C virus re-infection.   
 The 4 variables were assessed in relation to post-transplant CMV infection after 
discharge by univariate and multivariate analysis (Table 4).  Among them, mycophenolate 
mofetil (MMF) administration and CMV infection episodes during hospitalization were 
demonstrated as risk factors by univariate analysis (p=0.03, 0.04, each).  Both were possible 
predicting factors for CMV infection after discharge, but not to a statistically significant degree 
(p=0.06, 0.08, each). 
 
Discussion   
We initially did not have a defined policy of treating CMV antigenemia and no medication was 
given to the 7 patients who demonstrated CMV antigenemia without any related symptom.  
At the present, however, we start oral VGCG or intravenous GCV administration in all patients 
as soon as CMV antigenemia is demonstrated.  The rationale for starting preemptive therapy 
has been reported to be the prevention of immunomodulation by CMV that could be associated 
with infections with other opportunistic pathogens, inhibition of further progression to CMV 
disease, and consequent saving of resource utilization or costs (10).  VGCV is a valine ester 
prodrug of GCV, whose bioavailability is improved compared with GCV after oral 
administration, allowing the daily doses to be decreased (11), and this should allow patients to 
be given the medication without hospitalization with enough therapeutic efficacy (11).  In our 
institute, VGCV has been given since 2005 as a preemptive therapy for CMV infection, and all 
21 patients who showed CMV antigenemia improved on this drug.  
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Until now, various risk factors have been reported for CMV infection after liver transplantation 
(4, 8)(12).  We analyzed 18 variables and only ABO incompatible transplantation was 
demonstrated as a risk factor for CMV infection in both univariate and multivariate analyses 
(Tables 1 and 2).  The advantages and disadvantages of preemptive and universal prophylactic 
therapies with GCV or VGCV have been compared (2, 10, 13).  We began giving acyclovir or 
valacyclovir to recipients after LDLT as prophylactic therapy, mainly for the purpose of 
preventing the Herpes Simplex virus and Varicella Zoster virus infection.  Although 
prophylactic valacyclovir was demonstrated to reduce the incidence and delay the onset of CMV 
disease in renal transplantation recipients (14), little data are available on liver transplantation.  
While prophylactic therapy with GCV or VGCV was reported to reduce the rate of CMV 
infection or disease after solid organ transplantation, some reports demonstrated adverse 
effects of this strategy such as late-onset CMV infection and the emergence of drug-resistant 
CMV (8, 10).  Because eight ABO incompatible transplant patients with CMV infection 
showed an identical onset time of infection after the transplant operation, the rate of CMV 
disease and CMV attributable mortality compared with ABO identical / compatible transplant 
patients (data not shown), starting preemptive therapy after CMV antigenemia detection is 
deemed to be reasonable option, as it is in the case of ABO identical / compatible transplant 
patients.  In our series, we experienced one case of R (-) / D (+) transplantation.  This situation 
is well known as a significant risk factor for CMV infection, and prophylactic therapy with GCV 
or VGCV was recommended in several reports (13, 15 ).  We gave this recipient intravenous 
GCV immediately after the operation instead of oral valacyclovir, followed by oral VGCV for 5 
months without CMV infection occurring. 
 In general, beyond 6 months, most transplant recipients do relatively well and suffer from the 
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same infections seen in the general population with minimum immunosuppressant given (17).  
Because, however, we have sometimes experienced CMV infection in LDLT patients after 
discharge, we followed patients for 1 year after their operation in this study.  MMF was 
reported to be a risk factor for CMV disease in renal transplant recipients (18).  In our study, 
MMF administration predisposed patients to CMV infection with marginal significance by 
multivariate analysis (p=0.06), and MMF is likely to be a potential risk factor.  In our institute, 
MMF was given to patients, who were suspected of having acute cellular rejection with full 
doses of calcineurin inhibitor given, with ABO incompatible transplantation and to whom 
calcineurin inhibitor could not be given enough because of adverse effects, such as nephropathy.  
Additionally, all the patients were still taking steroids when they developed a CMV infection or 
disease after their discharge (Table 3).   
In summary, preemptive therapy after LDLT with either intravenous GCV or oral VGCV 
seems to be a reasonable option in terms of therapeutic efficacy, even with an ABO incompatible 
graft.  In the outpatient clinic, routine examinations as well as requested examinations for 
patients suspected of having CMV infection based on their symptoms, complaints, or findings 
are needed, especially under potentially over-immunosuppressive conditions.  However, the 
interval of the examination and until when such examinations should be conducted remains to 
be elucidated.   
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Figure 1.  Outcomes of patients with post-transplant cytomegalovirus infection or disease.  
 

Table 1. Comparison of patients with and without CMV infection during 
hospitalization by univariate analysis 





Age (year-old) 49.1 53.3 0.18 
Sex (male) 20 (64.5%) 27 (65.9%) 0.91 
Diabetes mellitus 6 (19.4%) 11 (26.8%) 0.50 
Fulminant hepatic failure 4 (12.9%) 1 (2.4%) 0.10 
HCV+/-HCC 11 (35.5%) 14 (34.1%) 0.91 
MELD score 20.9 18.5 0.23 
aGV/SLV (%) 46.3 50.4 0.21 
Emergent LDLT 6 (19.4%) 2 (4.9%) 0.06 
During of Surgery (minutes) 1,022 975 0.41 
Amount of blood loss (ml) 13,109 14,320 0.78 
Splenectomy 8 (25.8%) 8 (19.5%) 0.52 
ABO-incompatible 9 (29.0%) 2 (4.9%) 0.005 
Basiliximab injection 4 (12.9%) 5 (12.2%) 0.90 
Mycophenolate mofetil 
administration 
14 (45.2%) 11 (26.8%) 0.10 
Acute rejection 
(pathologically proven) 
12 (38.7%) 13 (31.7%) 0.54 
Steroid bolus injection 6 (19.4%) 9 (22.0%) 0.88 
Bacterial infection 15 (48.4%) 12 (29.3%) 0.10 
Re-operation 11 (35.5%) 9 (22.0%) 0.20 
NOTE: Data are numbers (%) of patients unless indicated otherwise.   
Abbreviations: CMV, cytomegalovirus; MELD, the model for end-stage liver 
disease; HCV, hepatitis C virus; HCC, hepatocellular carcinoma; aGV, actual 
graft volume; SLV, standard liver volume; LDLT, living donor liver 
transplantation. 
 
Table 2. Multivariable analysis of risk factors for CMV infection after living 
donor liver transplantation recipients 
Variable OR (95% Confidence Interval) p value 
Fulminant hepatic failure 4.41 (0.15 – 131.33) 0.39 
Emergent LDLT 2.92 (0.23 – 37.33) 0.41 
ABO-incompatible 5.89 (1.05 – 33.06) 0.04 
Bacterial infection 1.92 (0.62 – 5.89) 0.26 
Mycophenolate mofetil intake 2.71 (0.88 – 8.32) 0.07 























































1 24/F Biliary 
atresia 
no - 1 st+FK none VGCV alive 
2 16/M FHF no + 4 st+CyA+MMF none VGCV alive 
3 55/F HCV-LC/H
CC 
no - 2/10 st+CyA+MMF none VGCV alive 
4 67/M HCV-LC/H
CC 
no + 2/4/6/8 st+FK+MMF
→FK 
none VGCV dead 













6 25/M Caroli 
disease 
yes + 8 st+FK+MMF none VGCV alive 





yes + 5 st+FK+MMF none VGCV alive 
9 68/F HCV-LC/H
CC 
yes + 6 st+CyA+MMF none GCV alive 
10 52/M HCV-LC/H
CC 
no + 3 st+CyA fever GCV alive 
11 55/M Cryptogenic 
LC 
no + 2 st+FK none GCV alive 
12 65/F HCV-LC/H
CC 








Abbreviations: FHF, fulminant hepatic failure; st, steroid; CyA, cyclosporine A; 
MMF, mycophenolate mofetil; VGCV, valganciclovir; HCV, hepatitis C virus; LC, 
liver cirrhosis; HCC, hepatocellular carcinoma; FK, tacrolimus; GCV, 


















Table 4. Comparison of patients with and without CMV infection during out 
patient clinic by univariate analysis 
 





HCV-LC+/-HCC 6 (50.0%) 16 (31.4%) 0.19 








8 (66.7%) 17 (33.3%) 0.04 
NOTE: Data are numbers (%) of patients unless indicated otherwise.   
Abbreviations: CMV, cytomegalovirus; HCV. Hepatitis C virus; LC, liver 
cirrhosis; HCC, hepatocellular carcinoma. 
